Drug Trial Radar · NCT07491172
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jun 21, 2024
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- CRISPR Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Conditions
- Cardiovascular
- Metabolic Disease
- Dyslipidemias
- Lipid Disorder
- Hypertriglyceridemia
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Homozygous Familial Hypercholesterolemia (HoFH)
- Severe Hypertriglyceridemia (sHTG)
- Mixed Hyperlipemia
- Hypercholesterolaemia
Interventions
CTX310Drug
CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatmentsTime frame: From CTX310 infusion up to 12 months
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Integrity Clinical Research
Hialeah, Florida · Recruiting
Jacksonville Center for Clinical Research
Jacksonville, Florida · Recruiting
Flourish Orlando
Orlando, Florida · Recruiting
United Medical Research
Port Orange, Florida · Recruiting
University of Rochester
Rochester, New York · Recruiting
Duke Early Phase Clinical Research
Durham, North Carolina · Recruiting
Peters Medical Research
High Point, North Carolina · Recruiting
Oregon Health & Science University (OHSU)
Portland, Oregon · Recruiting
Royal Adelaide
Adelaide, Australia · Recruiting
CORE Research
Brisbane, Australia · Recruiting
Royal Prince Alfred Hospital
Camperdown, Australia · Not yet recruiting
Austin Health
Heidelberg, Australia · Recruiting
Monash Medical Center
Melbourne, Australia · Recruiting
Aotearoa
Auckland, New Zealand · Recruiting
NZCR
Christchurch, New Zealand · Recruiting
Royal Papworth Hospital
Cambridge, United Kingdom · Recruiting
Richmond Pharmacology
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.